Latebreakers: No real surprise to Exubera discontinuation, R.Ph.s say

Article

Exubera (inhaled insulin) discontinued

Pharmacists were not too surprised this month when Pfizer announced it was discontinuing sales of Exubera, the company's inhaled insulin, given the problems the product had from the beginning and the lack of acceptance among physicians and patients alike. Patients may have been expecting a device the size of an asthma inhaler, but instead they got something resembling a large flashlight that was difficult to hide even in a purse, one pharmacist said. Other complaints from patients included difficulty in dosing, with a 1-mg dose equivalent to three units of regular insulin, but 3 mg corresponding to eight units. It made calculating an appropriate dose difficult for patients, according to some pharmacists who dispensed Exubera. Sales were also thought to be low due to the high cost and poor reimbursement.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
© 2025 MJH Life Sciences

All rights reserved.